Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MidasLetterGuyon Apr 17, 2020 1:44pm
251 Views
Post# 30922852

RE:Should I put $45,000 in ATE?

RE:Should I put $45,000 in ATE?IMO, no. I just lightened up 10000 shares @ $0.75c from 18000 share position @ $0.43c purely from capital management purposes. That way, even if endpoint is missed at SP goes to $0.15c, position was still a money maker. Of course, I've capped my upside but capital preservation is a big part of investing. The big supply between $0.75-0.80 is likely other early investors (earlier than myself) derisking as well.

You could go red/black on what appears to be good odds of a good/great readout, but anything can happen. The best time to get in was a few months ago with the R/R was in a better place. Only because of the corornavirus crisis was I able to get in @0.43c again.

That said, buying here could still yield great results. But it's very risky. JMO.

Bullboard Posts